SCHEDULE: Sands Capital Boosts Inhibikase Therapeutics Stake to 10.8%

Sands Capital Life Sciences Pulse Fund II, L.P. and affiliates report a 10.8% beneficial ownership stake in Inhibikase Therapeutics, Inc.

Summary

• Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC, and Frank M. Sands (collectively, the "Reporting Persons") jointly reported beneficial ownership of 13,018,965 shares of Inhibikase Therapeutics, Inc. Common Stock.
• This ownership represents 10.8% of the company's outstanding Common Stock, based on 120,899,650 shares outstanding as of November 20, 2025.
• The Reporting Persons also hold Series A-1 warrants to purchase 5,475,000 shares and Series B-1 warrants to purchase 10,068,120 shares, which were acquired from the Issuer via a securities purchase agreement dated October 9, 2024.
• These warrants are not included in the current beneficial ownership calculation because they are not exercisable within 60 days of the filing date, and their exercise date is not yet determinable.
• The acquisition of these securities was not for the purpose of changing or influencing the control of Inhibikase Therapeutics, Inc.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as mildly positive. The establishment of a significant institutional stake by Sands Capital indicates investor confidence, although the non-exercisability of warrants within 60 days introduces some uncertainty regarding future share structure.

Positives

• A significant institutional investor, Sands Capital, has taken a substantial 10.8% stake in Inhibikase Therapeutics, which can signal confidence in the company's long-term prospects.
• The beneficial ownership is held by a reputable life sciences-focused fund, Sands Capital Life Sciences Pulse Fund II, L.P., indicating specialized investment interest.

Negatives

• The warrants held by Sands Capital, totaling over 15.5 million potential shares, are not exercisable within 60 days, meaning their conversion into common stock is not imminent and the exact timing is uncertain.
• There is a limitation on warrant exercise, preventing the holder from exceeding 19.99% beneficial ownership immediately after exercise, which caps potential immediate influence.

Risks

• The Series A-1 and Series B-1 warrants, representing a significant number of potential shares, are not exercisable within 60 days of the filing, and their exercise date is not determinable, creating uncertainty regarding future share dilution.
• The warrant agreements include a blocker provision, preventing the holder from exercising any portion of the warrants if it would result in beneficial ownership exceeding 19.99% of the outstanding Common Stock, limiting the investor's ability to increase their stake beyond this threshold through warrant conversion.

Future Outlook

The filing does not provide specific forward-looking statements or guidance from Inhibikase Therapeutics, Inc. It primarily details the current beneficial ownership of a significant investor.

Industry Context

StockSavvy.ai notes that a significant stake by a specialized life sciences fund like Sands Capital in a biotechnology company such as Inhibikase Therapeutics can be viewed positively by the market, suggesting a belief in the company's pipeline or strategic direction. This type of institutional investment often precedes increased analyst coverage or investor interest, particularly in the often volatile biotech sector where capital and strategic backing are crucial.

Stakeholder Impact

• Shareholders: The reporting of a significant institutional stake may instill confidence and potentially attract further investment. Future exercise of warrants could lead to dilution.
• Investors: Provides transparency regarding a major investor's position and potential future share issuance from warrant exercise.

Next Steps

• The Series A-1 warrant will become exercisable on the earlier of (a) the 75th calendar day following the initial filing date of the registration statement covering the resale of the underlying shares if the SEC reviews it, or (b) the fifth business day after the SEC notifies the Issuer that the registration statement will not be reviewed or is no longer subject to further review.
• The Series B-1 warrant will become exercisable on the same 'Initial Exercise Date' as the Series A-1 warrant, provided the Series A-1 warrant has been fully exercised.

Key Dates

Keywords

Inhibikase Therapeutics, Sands Capital, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Institutional Investment, Biotechnology, Life Sciences